Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31120302 | 0.90 | APP (0.81) | APPMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL5423269 | 0.86 | APP (0.81) | APPMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL2461395 | 0.84 | APP (1.00) | APPMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL4157441 | 0.84 | APP (0.72) | APPMAPTSMN1; SMN2SULT1A1KDM4E | |
| SCHEMBL14075967 | 0.84 | APP (0.72) | APPMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL30903625 | 0.83 | APP (0.71) | APPMAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL15414023 | 0.83 | APP (0.71) | APPMAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL13254486 | 0.83 | MAPT (0.70) | APPMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL2428611 | 0.81 | APP (0.63) | APPMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL11197691 | 0.81 | APP (0.68) | APPMAPTTP53THRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384966-B2 | 2-arylbenzothiazole derivatives | PHARMINXO LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | BARLAAM BERNARD | 2006-05-25 | — | — | US | disclosed |
| US-7045539-B2 | Therapeutic benzoxazole compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-20060063816-A1 | 2-Arylbenzothiazole derivatives | STEVENS MALCOLM F G | 2006-03-23 | — | — | US | disclosed |
| US-20040102435-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1345914-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051821-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102435-A1 | Therapeutic compounds | ESRRA, ESRRG, ESR2 | APP 277/4885MAPT 388/4885TP53 1001/4885 |
| US-20070208066-A1 | ER-beta-selective ligands | ESR2, ESRRG, ESRRA | APP 195/4885MAPT 592/4885TP53 1393/4885 |
| US-20060063816-A1 | 2-Arylbenzothiazole derivatives | CX3CR1, HCN2, CYBB | APP 1876/4885MAPT 4559/4885TP53 3085/4885 |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | ESR1, ESR2, ESRRG | APP 277/4885MAPT 221/4885TP53 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.